Working… Menu
Trial record 36 of 37 for:    Recruiting, Not yet recruiting, Available Studies | Receptor tyrosine kinase

A Phase II Evaluation of Afatinibin Patients With Persistent or Recurrent HER2-positive Uterine Serous Carcinoma (Afatinib)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT02491099
Recruitment Status : Recruiting
First Posted : July 7, 2015
Last Update Posted : November 11, 2019
Boehringer Ingelheim
Information provided by (Responsible Party):
Yale University

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2028
Publications of Results: